Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial

被引：53

作者：

Goto, K. ^{[1
]}

Sang-We, K. ^{[2
]}

Kubo, T. ^{[3
]}

Goto, Y. ^{[4
]}

Ahn, M-J. ^{[5
]}

Planchard, D.

Kim, D-W. ^{[6
,7
]}

Yang, J. C-H. ^{[8
]}

Yang, T-Y. ^{[9
]}

Pereira, K. M. C. ^{[10
]}

Saxena, K. ^{[11
]}

Shiga, R. ^{[11
]}

Cheng, Y. ^{[12
]}

Aregay, M. ^{[13
]}

Janne, P. A. ^{[14
]}

机构：

[1] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Japan

[2] Univ Ulsan, Oncol Dept, Coll Med, Asan Med Ctr, Seoul, South Korea

[3] Okayama Univ Hosp, Ctr Clin Oncol, Okayama, Japan

[4] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan

[5] Sungkyunkwan Univ, Dept Hematol & Oncol, Sch Med, Samsung Med Ctr, Seoul, South Korea

[6] Gustave Roussy, Dept Med Oncol, Villejuif, France

[7] Seoul Natl Univ Hosp, Seoul Natl Univ Coll Med, Dept Internal Med, Seoul, South Korea

[8] Natl Taiwan Univ Hosp, Dept Med Oncol, Taipei City, Taiwan

[9] Taichung Vet Gen Hosp, Chest Div Internal Med, Taichung, Taiwan

[10] Daiichi Sankyo Inc, Oncol R&D, Basking Ridge, NJ USA

[11] Daiichi Sankyo Inc, R&D, Basking Ridge, NJ USA

[12] Daiichi Sankyo Inc, Clin Safety & Pharmacovigilance, Basking Ridge, NJ USA

[13] Daiichi Sankyo Inc, BDM, Basking Ridge, NJ USA

[14] Dana Farber Canc Inst, Med Oncol, Boston, MA USA

来源：

关键词：

D O I：

10.1016/j.annonc.2022.08.057

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA55

引用

页码：S1422 / S1422

页数：1